



# ANONDITA MEDICARE LIMITED

AN ISO 9001:2015 ISO 13485:2016 & CDSO CERTIFIED CO.  
**Manufacturer of Condoms**

May 22, 2026

To,  
 The Manager,  
 Listing Compliance Department  
**National Stock Exchange of India Limited**  
 Exchange Plaza, Bandra Kurla Complex,  
 Bandra (East), Mumbai-400051

Subject: Statement of deviation or variation in the use of proceeds of Initial Public Offering under Regulation 32 of SEBI (LODR) Regulations, 2015.

SYMBOL: ANONDITA  
 ISIN: INE0VTV01012

Dear Sir/Madam,

Pursuant to Regulation 32 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019, please note that there are no deviation(s) or variation(s) in respect of the utilization of the proceeds of the Initial Public Offer ("IPO") of the Company during the half year ended March 31, 2026 as mentioned in the object clause of the Prospectus dated August 28, 2025.

Please find enclosed herewith the Statement of Deviation(s) or Variation(s) in the utilisation of funds raised through the Initial Public Offering ("IPO") of the Company for the half year ended March 31, 2026.

The above information is also being uploaded on the website of the Company <https://anonditamedicare.com/>.

Kindly take the above information on your records.

For and on behalf of  
 Anondita Medicare Limited

Bhawna Bisht  
 Company Secretary and Compliance officer  
 Membership No. A70843



UNIT



OFFICE



DIPPING AREA



TESTING AREA

Regd. Off.: Flat No. 704, Narmada Block N-6, Sector - D, Block - C, Vasant Kunj, New Delhi -110070  
 Corp Off. : D-001, Sector-80, Noida-201305, (U.P.) INDIA




# ANONDITA MEDICARE LIMITED

AN ISO 9001:2015 ISO 13485:2016 &amp; CDSCO CERTIFIED CO.

Manufacturer of Condoms

Statement of Deviation / Variation in utilisation of funds raised

Name of listed entity	Anondita Medicare Limited
Mode of Fund Raising	Initial Public Offer
Date of Raising Funds	28 <sup>th</sup> August, 2025
Amount Raised	6949 (in Lakhs)
Report filed for Quarter/ Half Year Ended	March 31, 2026
Monitoring Agency	Yes
Monitoring Agency Name, if applicable	Infomerics Valuation and Rating Limited
Is there a Deviation / Variation in use of funds raised	Yes
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Yes
If Yes, Date of shareholder Approval	February 12, 2026
Explanation for the Deviation / Variation	<p>As disclosed in the Prospectus dated 28 August 2025, the original objects of the issue were Capital Expenditure (CAPEX), Funding Working Capital Requirements, General Corporate Purposes (GCP) and Unidentified Acquisition.</p> <p>During the quarter ended September 30 2025 and December 31 2025 and March 31, 2026, certain modifications and reallocations were made in the utilization of IPO proceeds. Subsequently, the shareholders approved and ratified the revised utilization and reallocation of funds through a Special Resolution passed at the Extra-Ordinary General Meeting of the Members held on 12 February 2026.</p> <p>Accordingly:</p> <ul style="list-style-type: none"> <li>An amount of ₹278.41 lakhs was reallocated from General Corporate Purposes to Funding Working Capital Requirements, resulting in the revised allocation for working capital requirements increasing from ₹3500 Lakhs to ₹3778.41 Lakhs.</li> </ul>



UNIT



OFFICE



DIPPING AREA



TESTING AREA

Regd. Off.: Flat No. 704, Narmada Block N-6, Sector - D, Block - C, Vasant Kunj, New Delhi -110070

Corp Off. : D-001, Sector-80, Noida-201305, (U.P.) INDIA

Tel : 0120 4520200/4123 4567 8900 (400 lines) Fax : 0120 4520201



# ANONDITA MEDICARE LIMITED

AN ISO 9001:2015 ISO 13485:2016 & CDSCO CERTIFIED CO.

Manufacturer of Condoms

	<ul style="list-style-type: none"> <li>The allocation towards General Corporate Purposes and Unidentified Acquisition was revised from ₹2015.87 Lakhs to ₹1737.46 Lakhs and shall now be utilized only towards General Corporate Purposes within the revised regulatory limits. No unidentified acquisition shall be undertaken using the IPO proceeds.</li> <li>The Company has also revised the deployment timeline of funds under General Corporate Purposes. The entire balance amount was originally expected to be utilized within FY 2025–26; however, the remaining balance of Rs. 123.25 Lakhs shall now be utilized during FY 2026–27.</li> <li>Further, the utilization towards working capital requirements increased due to expansion in the scale of operations and higher working capital needs. The original estimates were based on a projected turnover of ₹10,000 Lakhs for FY 2025–26, which was revised to approximately ₹14,500 Lakhs.</li> <li>There is no material variation in the Capital Expenditure object except changes and/or additions to vendors, as disclosed in the Prospectus.</li> </ul>
Comments of the Audit Committee after review	Not Applicable(NA)
Comments of the auditors, if any	Not Applicable(NA)

Objects for which funds have been raised and where there has been a deviation, in the following table

Original Object	Modified Object, if any	Original Allocation (in Lakhs)	Modified allocation, if any (in Lakhs)	Funds Utilised (in Lakhs)	Amount of Deviation/ Variation for the quarter according to applicable	Remarks if any



Regd. Off.: Flat No. 704, Narmada Block N-6, Sector - D, Block - C, Vasant Kunj, New Delhi -110070

Corp Off. : D-001, Sector-80, Noida-201305, (U.P.) INDIA

Tel : 0120 4520200/4102 4102 4102 4102 4102 4102 4102 4102 4102 4102



# ANONDITA MEDICARE LIMITED

AN ISO 9001:2015 ISO 13485:2016 & CDSCO CERTIFIED CO.

Manufacturer of Condoms

			Lakhs)		according to applicable object(in Lakhs)	
<b>Capex</b>	No variation in object of the issue except changes and/or additions to vendors, as disclosed in the Prospectus	600	No Change	262.10	NA	NA
<b>Funding Working Capital Requirements</b>	<p>Due to revision in GCP limits (from 35% to 25%) under the revised SEBI guidelines, an amount of Allocation of Rs. 278.41 Lacs out of Object 3 (i.e., General Corporate Purposes) towards funding the Company's working capital requirements, including working capital loans and Cash Credit (CC) limits and with this reallocation, the revised total allocation for working capital now stands at Rs. 3,778.41 Lacs.</p> <p>Furthermore, utilization under this object has exceeded the originally estimated utilization during financial year 2025-26 and 2026-27 due to the Company's expanded scale of operations and higher working capital requirements and the working capital estimates were initially based on a projected turnover of ₹100 crore for FY 2025-26, which has now been revised to approximately ₹145 crore.</p>	3500	3778.41	3575.55	NA	NA
<b>General Corporate</b>	Due to revision in GCP limits (from 35% to 25%) under the revised SEBI guidelines, the funds	2015.87	1737.46	1614.21	NA	NA



UNIT



OFFICE



DIPPING AREA



TESTING AREA

Regd. Off.: Flat No. 704, Narmada Block N-6, Sector - D, Block - C, Vasant Kunj, New Delhi -110070

Corp Off. : D-001, Sector-80, Noida-201305, (U.P.) INDIA

Tel : 0120-4520200/41212411/00 (400 Lines) Fax : 0120-4520201




# ANONDITA MEDICARE LIMITED

AN ISO 9001:2015 ISO 13485:2016 & CDSCO CERTIFIED CO.

## Manufacturer of Condoms

<p>(GCP) 1. f or Unidenti ed Acquisitio n 2. For GCP (Capped at 25% of gross issue size)</p>	<p>Object 3 (Unidentified Acquisition and General Corporate Purposes) will be utilized for GCP only, now restricted to 25% of the total IPO proceeds. Any amount excess of GCP Limit will be transferred towards meeting the Company's working capital requirements.</p> <p>No unidentified acquisition will be undertaken using the IPO proceeds.</p> <p>Furthermore, the allocation of Rs. 278.41 Lacs from Object 3 to Object 2 for funding the Company's working capital requirements, including working capital loans and Cash Credit Limit. With this reallocation, the revised total allocation for General Corporate Purposes stands at Rs. 1,737.46 Lacs.</p> <p>Further, while the utilization of these funds was initially projected over FY 2025-26 and FY 2026-27, it was subsequently expected that the entire allocation would be deployed within FY 2025-26. However, the balance amount shall now be utilized during the current financial year 2026-27.</p>					
<p>Issue Related Expenses</p>	<p>NA.</p>	<p>833.13</p>	<p>-</p>	<p>824.01</p>	<p>NA</p>	<p>NA</p>

For and on behalf of  
Anondita Medicare Limited



Anupam Ghosh  
Managing Director  
DIN: - 02675517  
Address: D-001, Sector 80, Gautam Buddha Nagar,  
Noida, Uttar Pradesh-201305

DATE : MAY 22, 2026



Regd. Off.: Flat No. 704, Narmada Block N-6, Sector - D, Block - C, Vasant Kunj, New Delhi -110070  
Corp Off. : D-001, Sector-80, Noida-201305, (U.P.) INDIA

Tel : 0120 452000/452001/452002/452003/452004/452005/452006/452007/452008/452009/452010